Abstract
Background: Chronic obstructive pulmonary disease (COPD) is displayed as the obstruction of the small airways and includes “flare-ups”, sudden and significant worsening of symptoms, sometimes caused by infections.
Methods: COPD (n=38) and acute bronchitis (AB, n=35) patients were grouped based on age and examined at two time points: during flare-ups/infections and at day 30. We measured various biomarkers, including total plasma TGF-β1 levels, total IgA, total IgM, and Pseudomonas aeruginosa specific IgA levels.
Results: Increased TGF-β1 levels were detected in COPD patients, with no significant change observed at day 30. A significant lowering of total plasma IgA level was observed in COPD patients on day 30. No significant difference in specific P. aeruginosa IgA levels were observed between the two patient groups, or over time. Interestingly, a correlation between total IgM and IgA levels was absent in COPD patients. While positive correlation between age and IgA level existed in acute bronchitis patients, this correlation was negative in COPD patients. A significant correlation was observed between total IgA and P. aeruginosa specific IgA in acute bronchitis patients. On the other hand, COPD patients showed no correlation at t=0 but a correlation was seen between total IgA and P. aeruginosa specific IgA1 at t=30, implying that flare-up resolution is accompanied with consolidation, a corresponding reinforcement or stabilization, of P. aeruginosa specific IgA levels in COPD patients.
Conclusion: Here we report on deregulated IgA - IgM axis in COPD, and call for thorough, larger scale studies of the humoral immune system in this pathology.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.